Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.

Article  PubMed  CAS  Google Scholar 

Phillips JM, Parish NM, Raine T, Bland C, Sawyer Y, De La Peña H, et al. Type 1 diabetes development requires both CD4 + and CD8 + T cells and can be reversed by non-depleting antibodies targeting both T cell populations. Rev Diabet Studies: RDS. 2009;6:97.

Article  PubMed  PubMed Central  Google Scholar 

Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol. 2010;204:1.

Article  PubMed  CAS  Google Scholar 

Venables MC, Jeukendrup AE. Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. Diab/Metab Res Rev. 2009;25:S18–23.

Article  CAS  Google Scholar 

Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. Diabetes 2013:1–11.

Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64.

Article  PubMed  PubMed Central  Google Scholar 

Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol. 2010;25:1207–17.

Article  PubMed  PubMed Central  Google Scholar 

Riedel MJ, Kieffer TJ. Treatment of diabetes with glucagon-like peptide-1 gene therapy. Expert Opin Biol Ther. 2010;10:1681–92.

Article  PubMed  CAS  Google Scholar 

Samms RJ, Christe ME, Collins KA, Pirro V, Droz BA, Holland AK et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Investig 2021;131.

Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metabolism. 2018;20:5–21.

Article  CAS  Google Scholar 

Han V, Hynes M, Jin C, Towle A, Lauder J, Lund P. Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain. J Neurosci Res. 1986;16:97–107.

Article  PubMed  CAS  Google Scholar 

Larsen P, Tang-Christensen M, Holst J, Ørskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77:257–70.

Article  PubMed  CAS  Google Scholar 

Bodnaruc AM, Prud’homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metabolism. 2016;13:1–16.

Article  Google Scholar 

Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–90.

Article  PubMed  Google Scholar 

Turton M, O’shea D, Gunn I, Beak S, Edwards C, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72.

Article  PubMed  CAS  Google Scholar 

Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Investig. 1998;101:515–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–42.

Article  PubMed  CAS  Google Scholar 

Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–70.

Article  PubMed  CAS  Google Scholar 

Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metabol. 2016;24:15–30.

Article  CAS  Google Scholar 

Mieczkowska A, Bouvard B, Chappard D, Mabilleau G. Glucose-dependent insulinotropic polypeptide (GIP) directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures. Bone. 2015;74:29–36.

Article  PubMed  CAS  Google Scholar 

Garg G, McGuigan FE, Kumar J, Luthman H, Lyssenko V, Akesson K. Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: an association analysis of polymorphisms and bone in young and elderly women. Bone Rep. 2016;4:23–7.

Article  PubMed  CAS  Google Scholar 

Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol 2021:1040.

Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF. Physiology of the Incretin Hormones, GIP and GLP-1—Regulation of release and posttranslational modifications. Compr Physiol. 2011;9:1339–81.

Google Scholar 

Holst JJ. The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 2019;96:46–55.

Article  PubMed  CAS  Google Scholar 

Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold Re, et al. Glucagon-like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992;22:283–91.

Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL, et al. Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia. 2018;61:284–94.

Article  PubMed  CAS  Google Scholar 

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

Article  PubMed  CAS  Google Scholar 

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525–36.

Article  PubMed  CAS  Google Scholar 

Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Investig. 1996;97:92–103.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Madsbad S, Kehlet H, Hilsted J, Tronier B. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes. 1983;32:436–8.

Article  PubMed  CAS  Google Scholar 

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig. 1993;91:301–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Meier J, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt W, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003;46:798–801.

Article  PubMed  CAS  Google Scholar 

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.

Article  PubMed  CAS  Google Scholar 

Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiology-Endocrinology Metabolism. 2004;287:E199–206.

Article  CAS  Google Scholar 

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiology-Endocrinology Metabolism. 1997;273:E981–8.

Article  CAS  Google Scholar 

Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Investig. 1981;68:1106–7.